PolyPid Ltd. has unveiled promising pharmacokinetic data from its Phase 3 SHIELD II trial of D-PLEX₁₀₀, a novel local antibiotic delivery system designed to prevent surgical site infections (SSIs) following abdominal colorectal surgery. The trial results, set to be presented at the ESCMID Global 2026 congress, demonstrate that D-PLEX₁₀₀ achieves sustained doxycycline release for up to 763 hours post-application, with minimal systemic exposure—plasma concentrations remaining below 100 ng/mL compared to significantly higher levels seen with oral doxycycline.

These findings underscore the therapeutic potential of D-PLEX₁₀₀ in addressing a critical gap in current SSI prophylaxis strategies. By maintaining local antimicrobial activity for a full 30 days at the surgical site, D-PLEX₁₀₀ effectively mitigates the risks associated with conventional systemic antibiotics, particularly during the high-risk post-surgical period when infections are most likely to occur. The trial reported a 60% relative risk reduction in SSI incidence, a statistically significant outcome (p=0.0013), reinforcing the efficacy of this targeted approach.

The implications for the field are substantial. D-PLEX₁₀₀’s Breakthrough Therapy designation from the FDA highlights its potential to transform surgical care protocols and expedite the development of localized antibiotic therapies. This advancement not only shifts the paradigm for SSI prevention but also opens avenues for further research into controlled-release systems for other therapeutic agents, potentially enhancing treatment outcomes across various surgical and medical contexts.

Source: globenewswire.com